---
title: "Runben Biotechnology's major shareholder JNRY VIII has completed a 3% share reduction"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/227730530.md"
description: "According to the Zhitong Finance APP, Runben Biotechnology announced that its shareholder JNRY VIII HK Holdings Limited (referred to as \"JNRY VIII\"), which holds more than 5% of the shares, has cumulatively reduced its holdings by 12.1378 million shares, accounting for 3.00% of the total share capital. This reduction plan has been completed"
datetime: "2025-02-10T10:38:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/227730530.md)
  - [en](https://longbridge.com/en/news/227730530.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/227730530.md)
generator: "portal-rs"
---

# Runben Biotechnology's major shareholder JNRY VIII has completed a 3% share reduction

According to the Zhitong Finance APP, Runben Biotechnology (603193.SH) announced that its shareholder holding more than 5%, JNRY VIII HK Holdings Limited (referred to as "JNRY VIII"), has cumulatively reduced its holdings by 12.1378 million shares, accounting for 3.00% of the total share capital. This reduction plan has been completed

### Related Stocks

- [603193.CN](https://longbridge.com/en/quote/603193.CN.md)

## Related News & Research

- [There's A Lot To Like About Zur Shamir Holdings' (TLV:ZUR) Upcoming ₪0.0916074 Dividend](https://longbridge.com/en/news/297594921.md)
- [SOTL: Record revenue, margin expansion, and innovation drive robust growth and future optimism](https://longbridge.com/en/news/297615048.md)
- [Diversified Royalty announces $0.02375 September dividend per share](https://longbridge.com/en/news/297959336.md)
- [YieldMax BABA Option Income Strategy ETF declares $0.0589 dividend](https://longbridge.com/en/news/297826141.md)
- [Cordyceps Sunshine Biotech launches unregistered share sale up to US$ 15 million at US$ 2.52 each](https://longbridge.com/en/news/297782594.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**